Literature DB >> 20166765

Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Fredrick Hagemeister1.   

Abstract

Rituximab is a monoclonal antibody that is widely utilized in the treatment of a number of B-cell-derived haematological malignancies. Rituximab, in combination with chemotherapy, has significantly improved survival outcomes for patients diagnosed with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), the two most commonly diagnosed subtypes of non-Hodgkin's lymphoma. Furthermore, chemoimmunotherapy containing rituximab has led to significant increases in complete response and progression-free survival rates for patients with both previously untreated and relapsed or refractory chronic lymphocytic leukaemia (CLL). This article reviews the efficacy data from clinical trials demonstrating the significant survival benefits associated with rituximab use in the treatment of FL, DLBCL and CLL.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20166765     DOI： 10.2165/11532180-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  48 in total

1.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

Authors:  N Di Gaetano; Y Xiao; E Erba; R Bassan; A Rambaldi; J Golay; M Introna
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

2.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

3.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Authors:  S Alas; C Emmanouilides; B Bonavida
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

5.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.

Authors:  D Shan; J A Ledbetter; O W Press
Journal:  Cancer Immunol Immunother       Date:  2000-03       Impact factor: 6.968

Review 6.  Empowering targeted therapy: lessons from rituximab.

Authors:  Adam J Olszewski; Michael L Grossbard
Journal:  Sci STKE       Date:  2004-07-06

7.  Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

Authors:  R García-Sanz; A Orfão; M González; M D Tabernero; J Bladé; M J Moro; J Fernández-Calvo; M A Sanz; J A Pérez-Simón; A Rasillo; J F Miguel
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

Review 8.  Management and preparedness for infusion and hypersensitivity reactions.

Authors:  Heinz-Josef Lenz
Journal:  Oncologist       Date:  2007-05

Review 9.  Ten years of rituximab in NHL.

Authors:  Matthew C Winter; B W Hancock
Journal:  Expert Opin Drug Saf       Date:  2009-03       Impact factor: 4.250

10.  Emerging treatments for indolent lymphoma.

Authors:  Bruce D Cheson; Stephanie A Gregory; Robert Marcus
Journal:  Clin Adv Hematol Oncol       Date:  2007-05
View more
  21 in total

Review 1.  Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

Review 2.  CD19 as an attractive target for antibody-based therapy.

Authors:  Ohad Hammer
Journal:  MAbs       Date:  2012-07-23       Impact factor: 5.857

Review 3.  Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 4.  Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

5.  Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?

Authors:  David J Riese
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

Review 6.  Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.

Authors:  Fredrick B Hagemeister
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 7.  Pathogenesis of Graves' orbitopathy: a 2010 update.

Authors:  T J Smith
Journal:  J Endocrinol Invest       Date:  2010-06       Impact factor: 4.256

8.  Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.

Authors:  Kyohei Nakamura; Mika Casey; Harald Oey; Frank Vari; John Stagg; Maher K Gandhi; Mark J Smyth
Journal:  Leukemia       Date:  2020-04-08       Impact factor: 11.528

9.  Efficient B cell depletion via diphtheria toxin in CD19-Cre/iDTR mice.

Authors:  Filiz Demircik; Thorsten Buch; Ari Waisman
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

Review 10.  Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications.

Authors:  Fan-Lin Kong; Richard J Ford; David J Yang
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.